Pharmaceutical composition
AssigneeSankyo Company, Limited
InventorsTakafumi Kohama, Toshimori Inaba
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical composition for administering simultaneously, separately or sequentially N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and a HMG-COA reductase inhibitor. The composition has an excellent lipid lowering action and excellent progress inhibitory effects on atherosclerosis, has excellent progress inhibitory effects on atherosclerosis in the aorta, has excellent onset inhibitory effects on xanthoma occurring in limb joints, and is useful as a preventive or therapeutic agent for atherosclerosis or xanthoma.
Claims28
A pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-COA reductase inhibitor.
The pharmaceutical composition comprising N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-CoA reductase inhibitor.
A method of prevention or treatment of atherosclerosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide or a pharmacologically acceptable salt thereof, and an HMG-COA reductase inhibitor.
A method of prevention or treatment of atheroscerlosis or xanthoma comprising administering to a human patient in need thereof, an effective amount of a combination of agents comprising N-(1-octyl-5-carboxymethyl-4, 6-dimethylindolin-7-yl)-2,2-dimethylpropanamide sulfate, and a HMG-COA reductase inhibitor.
Dependencies are inferred from the claim text.